Aktie NABRIVA THERAPEUTICS PLC - ADR
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Nabriva Therapeutics PLC - ADR Nasdaq

Aktien

US62957M1045

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.
Nabriva Therapeutics : Failure to Satisfy Listing Rule - Form 8-K
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer
Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023
NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt
Merck : fin de l'accord de distribution avec Nabriva
Nabriva Therapeutics : Material Agreement - Form 8-K
NABRIVA THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
NABRIVA THERAPEUTICS PLC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer
Nabriva Therapeutics : Termination of Material Agreement - Form 8-K
NABRIVA THERAPEUTICS PLC : Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)
Nabriva Therapeutics Provides Corporate Update
Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DWGH Aktie
  4. Aktie
  5. Nachrichten Nabriva Therapeutics PLC - ADR
  6. Andere Sprachen